292 related articles for article (PubMed ID: 38191498)
1. Vaccines: a promising therapy for myelodysplastic syndrome.
Gera K; Chauhan A; Castillo P; Rahman M; Mathavan A; Mathavan A; Oganda-Rivas E; Elliott L; Wingard JR; Sayour EJ
J Hematol Oncol; 2024 Jan; 17(1):4. PubMed ID: 38191498
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients.
Robinson TM; Prince GT; Thoburn C; Warlick E; Ferguson A; Kasamon YL; Borrello IM; Hess A; Smith BD
Leuk Lymphoma; 2018 Dec; 59(12):2801-2811. PubMed ID: 29616857
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
4. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndrome hematopoietic stem cell.
Li J
Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
Linder K; Lulla P
Hum Vaccin Immunother; 2021 Aug; 17(8):2602-2616. PubMed ID: 33941042
[TBL] [Abstract][Full Text] [Related]
8. Management of older adults with myelodysplastic syndromes (MDS).
Luskin MR; Abel GA
J Geriatr Oncol; 2018 Jul; 9(4):302-307. PubMed ID: 29290596
[TBL] [Abstract][Full Text] [Related]
9. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.
Bhatt VR; Steensma DP
J Oncol Pract; 2016 Sep; 12(9):786-92. PubMed ID: 27621329
[TBL] [Abstract][Full Text] [Related]
11. Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman DA; Davila ML
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S26-S30. PubMed ID: 28760299
[TBL] [Abstract][Full Text] [Related]
12. Cancer immune therapy for myeloid malignancies: present and future.
Holmström MO; Hasselbalch HC
Semin Immunopathol; 2019 Jan; 41(1):97-109. PubMed ID: 29987478
[TBL] [Abstract][Full Text] [Related]
13. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services.
Giralt SA; Horowitz M; Weisdorf D; Cutler C
J Clin Oncol; 2011 Feb; 29(5):566-72. PubMed ID: 21220586
[TBL] [Abstract][Full Text] [Related]
14. Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS).
Mann M; Brunner AM
Curr Probl Cancer; 2022 Feb; 46(1):100824. PubMed ID: 34980485
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
16. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
17. Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).
Atallah E; Bylow K; Troy J; Saber W
Curr Hematol Malig Rep; 2014 Mar; 9(1):57-65. PubMed ID: 24398726
[TBL] [Abstract][Full Text] [Related]
18. What are the most promising new agents in myelodysplastic syndromes?
Chandhok NS; Boddu PC; Gore SD; Prebet T
Curr Opin Hematol; 2019 Mar; 26(2):77-87. PubMed ID: 30632987
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Chua CC; Fleming S; Wei AH
Best Pract Res Clin Haematol; 2019 Mar; 32(1):3-12. PubMed ID: 30927972
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
